Xing-Le Liang

Xing-Le Liang

Auto-generated profile, based on publicly available information

Xing-Le Liang

Chinese Medicine Guangdong Laboratory, Department of Nephrology, The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Nursing Management
Verified
Journal Article
Open access
HCHui-Fen Chen
Hui-Fen Chen
XLXing-Le Liang
Xing-Le Liang
YHYan Han
Yan Han
YSYu-Han Shen
Yu-Han Shen
XZXian-Long Zhang
Xian-Long Zhang
YWYi-fan Wu
Yi-fan Wu
Background: Self‐management (SMP) is a novel treatment comprised of multidimensional interventions. Researchers have reported its reliable effects on short‐term improvements in surrogate indicators like 24‐h urinary protein excretion and systolic blood pressure. However, whether it has any effect on long‐term changes in other surrogate indicators and chronic kidney disease (CKD) endpoints remains unclear. Methods: Patients with CKD stages 3‐4 were grouped into either a SMP group or a nonself‐management (non‐SMP) group whether they had complied any of five characterized elements: regular visits, medication adjustment, nutritional intervention, lifestyle modification, education, and behavior guide. We used 1:1 nearest‐neighbor propensity score matching (PSM) to balance between‐group differences. Cox regression was used to explore the long‐term association between SMP and composite outcomes (all‐cause mortality, end‐stage kidney disease (ESKD), ≥ 50% decline in estimated glomerular filtration rate (eGFR), or doubling of serum creatinine (SCr) from baseline). Linear mixed‐effects (LME) model and marginal means comparisons were used to surrogate indicators analysis. Results: The study included 1160 patients with a median follow‐up of 27.20 months. Among them, 580 individuals were in the SMP group and 580 were in the non‐SMP group. In the non‐SMP group, the median follow‐up was 24.48 (12.21, 43.39) months with 174 (30.00%) events, whereas the SMP group had a median follow‐up of 29.34 (14.75, 42.00) months with 134 (23.10%) composite outcomes. Participation in a SMP program was associated with a 30.9% reduction in CKD progression risk (hazard ratio (HR) of composite outcome: 0.691, 95% CI: 0.549–0.869, and p = 0.002). LME and marginal means comparison indicated that patients with SMP had higher mean difference of eGFR and serum albumin (Alb) than the non‐SMP individuals (mean difference of eGFR: 1.791 (0.721, 2.861) mL/min/1.73 m 2 , p = 0.001; marginal mean difference of eGFR: 2.560 (1.660, 3.470) mL/min/1.73 m 2 , p < 0.0001; mean difference of Alb: 0.654 (0.202, 1.105) g/L, p = 0.005; and marginal mean difference of Alb: 0.460 (0.166, 0.753) g/L, p = 0.002). Conclusion: SMP programs are associated with a 30.9% reduction in CKD progression risk and improvements in kidney function and nutrition‐related surrogate markers, benefiting CKD patients in stages 3‐4.